CD38 and plasma cell myeloma: In addition, Daratumumab reduces the types of inhibitory cells in the TME of multiple myeloma, i.e., it consumes immuno-suppressive cells such as CD38+ MDSCs, Tregs, and Bregs, and enhances anti-tumor activity (1).